Abstract

Chloroplast engineering (or chloroplast transformation technology, CTT) is a strategy consisting of inserting a transgene into the chloroplast genome of a plant instead of its nuclear genome. CTT brings advantages such as control of the site of gene insertion, high rates of transgene expression and protein accumulation, lack of transmission of the transgene via pollen due to the fact that plastid genes are maternally inherited and an absence of epigenetic effects. Tobacco remains the species most amenable to CTT to date, although chloroplast genetic engineering has also been achieved successfully in crops such as maize, tomato, cotton, potato, rice and sugar beets. Improving agricultural traits such as herbicide and pathogen resistance, resistance to drought, salt tolerance and phytoremediation potential are all promising applications. Molecular pharming is another area of chloroplast engineering with high potential; the production of a wide range of products such as vaccine antigens, pharmaceutical proteins (human somatotropin, human serum albumin, human interferon, monoclonal antibodies) and industrial proteins (avidin, beta casein, liquid crystal polymers, xylanase, anthranilate synthase) is economically beneficial in comparison with bacterial cultivation or animal cell cultures. This review summarises the current status of CCT and its potential economic impact from the viewpoint of high levels of transgene expression and high accumulation of foreign proteins.  

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call